Key HighlightsARK Invest offloaded 84,392 Alphabet shares valued at $28.6 million on Sept 9, 2026The firm acquired 43,091 Meta Platforms shares worth $26.4 million following Meta’s Muse AI agent unveilingMeta shares surged 6.55% while Alphabet declined 2.28% that trading dayARK expanded positions in Beam Therapeutics, CRISPR Therapeutics, and Intellia TherapeuticsThe firm reduced its Tempus AI holdings by approximately $1.5 millionCathie Wood’s investment firm ARK Invest executed significant portfolio adjustments on Wednesday, Sept 9, 2026. The company divested 84,392 Alphabet shares valued at approximately $28.6 million through its ARKK and ARKW exchange-traded funds.Alphabet Inc., GOOGLSimultaneously, ARK purchased 43,091 Meta Platforms shares totaling around $26.4 million. Meta’s stock price climbed 6.55% during the session following the company’s introduction of Muse, an innovative AI agent designed to manage activities including online shopping, travel arrangements, and email management.Meta’s chief executive Mark Zuckerberg characterized the technology as integral to the company’s vision of achieving “personal superintelligence.” The announcement provided shareholders with tangible evidence of Meta’s artificial intelligence investment strategy.The social media giant anticipates capital expenditures ranging from $130 billion to $145 billion throughout the current fiscal year, with substantial allocations directed toward AI infrastructure and development.Alphabet stock experienced a 2.28% decline during the same trading session. Mizuho Securities analyst Lloyd Walmsley suggested Meta’s Muse introduction might reignite investor apprehension regarding Google’s Gemini AI technology and potential disruption to conventional search engine revenues from AI-powered agents.ARK has been systematically decreasing its Alphabet allocation across multiple trading sessions. Wednesday’s transaction represents a continuation of this established pattern rather than an isolated strategic shift.Biotech Portfolio ExpansionARK simultaneously strengthened multiple biotechnology positions during Wednesday’s trading. The investment firm acquired 271,159 Beam Therapeutics shares valued at roughly $7.3 million. Beam’s stock declined 6.17% to $25.18 following the company’s release of revised Phase 1/2 clinical trial results for BEAM-302, an experimental therapy targeting alpha-1 antitrypsin deficiency.The firm purchased 47,113 CRISPR Therapeutics shares totaling approximately $2.6 million. CRISPR stock decreased 2.43% to $53.45 during the session.ARK also accumulated 204,206 Intellia Therapeutics shares worth about $2.6 million. Intellia’s stock price fell 4.16% to $12.21.The Food and Drug Administration recently granted Intellia’s lonvo-z application Priority Review status. Regulatory determination is anticipated by March 10, 2027. Upon approval, lonvo-z would represent the inaugural single-administration therapy for hereditary angioedema utilizing in vivo CRISPR gene modification technology.Among divestitures, ARK decreased its Tempus AI position by 22,767 shares worth approximately $1.5 million. Tempus stock declined 4.68% throughout the trading day. ARK has systematically reduced its Tempus allocation over multiple recent sessions.ARK’s September 9 transactions demonstrate a strategic reallocation from Alphabet toward Meta Platforms and biotechnology equities, capitalizing on price corrections while reducing exposure to underperforming holdings.The post ARK Invest Exits $28M Alphabet (GOOGL) Position, Piles Into Meta (META) Stock appeared first on Blockonomi.